Sone Kazuki, Oguri Tetsuya, Ito Keima, Kitamura Yuki, Inoue Yoshitsugu, Takeuchi Akira, Fukuda Satoshi, Takakuwa Osamu, Maeno Ken, Asano Takamitsu, Kanemitsu Yoshihiro, Ohkubo Hirotsugu, Takemura Masaya, Ito Yutaka, Niimi Akio
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan.
Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
Anticancer Res. 2017 Sep;37(9):5125-5131. doi: 10.21873/anticanres.11932.
BACKGROUND/AIM: The aim of the present study was to determine the clinical value of tumor marker levels for previously treated NSCLC patients.
We retrospectively screened 113 previously treated patients with advanced NSCLC who were treated with docetaxel monotherapy regarding the pretreatment serum level of cytokeratin 19 fragment (CYFRA21-1) and carcinoembryonic antigen (CEA).
The thirty-two patients with normal CYFRA21-1 levels and high CEA levels had a significantly higher response rate than the other 81 patients (25% vs. 8.6%, p=0.031). The former group showed statistically longer progression-free survival (PFS) and overall survival (OS) than the latter group (median PFS, 180 vs. 59 days, p<0.001; median OS, 579 vs. 255 days, p=0.002). In multivariate analysis, tumor marker levels had a significant impact on PFS and OS.
Combination of the two tumor markers is a predictive and prognostic marker of docetaxel monotherapy for previously treated NSCLC patients.
背景/目的：本研究的目的是确定肿瘤标志物水平对既往接受过治疗的非小细胞肺癌（NSCLC）患者的临床价值。
我们回顾性筛选了113例既往接受过治疗的晚期NSCLC患者，这些患者接受了多西他赛单药治疗，分析其预处理时细胞角蛋白19片段（CYFRA21-1）和癌胚抗原（CEA）的血清水平。
CYFRA21-1水平正常且CEA水平高的32例患者的缓解率显著高于其他81例患者（25%对8.6%，p=0.031）。前一组的无进展生存期（PFS）和总生存期（OS）在统计学上显著长于后一组（中位PFS，180天对59天，p<0.001；中位OS，579天对255天，p=0.002）。在多变量分析中，肿瘤标志物水平对PFS和OS有显著影响。
两种肿瘤标志物的联合是既往接受过治疗的NSCLC患者多西他赛单药治疗的预测和预后标志物。
